肺纤维化患者血清及诱导痰肺表面活性蛋白水平测定及意义

摘要

Objective To explore levels and the clinical significance of serum and induced sputum (SP)‐D in patients with acute exacerbation of idiopathic pulmonary fibrosis (AEIPF). Methods The contents of serum and in‐duced sputum SP‐D for 26 patients with AEIPF and stable IPF were detected by ELISA, 42 cases of healthy people were choosen as control group. Results Average serum SP‐D levels in patients who experienced an acute exacerba‐tion and remission were (196 ± 82), (125 ± 69)ng/mL, respectively, the control group was (96 ± 47)ng/mL, induced sputum SP‐D was(153 ± 71), (106 ± 64)ng/mL. The serum SP‐D for patients with COPD in acute exacerbation stage was significantly higher than that for patients in stable stage and controls (P<0. 05). Conclusion The serum SP‐D may be a potential diagnostic biomarker for AEIPF.%目的：检测特发性肺纤维化患者急性加重期血清及诱导痰肺表面活性蛋白D（SP‐D）水平并探讨其临床治疗意义。方法选择特发性肺纤维化患者急性加重期住院治疗26例，分别收集纳入患者入院时及治疗后病情缓解血清及诱导痰液标本，采用酶联免疫吸附试验检测血清及诱导痰S P‐D水平。选择42例健康人群作为对照组。结果特发性肺纤维化患者急性加重期及病情缓解期血清SP‐D平均水平分别为（196±82）、（125±69）ng／mL ，健康对照组为（96±47）ng／mL ，诱导痰SP‐D平均水平为（153±71）、（106±64）ng／mL ，急性加重期与缓解期及健康对照组SP‐D水平比较差异有统计学意义（P＜0．05）。结论血清SP‐D检测可作为特发性肺纤维化患者急性加重诊断的生物学指标。